{"id":44367,"date":"2022-05-26T10:01:28","date_gmt":"2022-05-26T08:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/"},"modified":"2022-05-26T10:01:28","modified_gmt":"2022-05-26T08:01:28","slug":"biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/","title":{"rendered":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents"},"content":{"rendered":"
\n

\nAddition of Aalto Bio Reagents expands Biosynth Carbosynth\u2019s offer to its clinical diagnostics customers.<\/i>\n<\/p>\n

STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (\u201cBiosynth\u201d), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (\u201cAalto\u201d), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.\n<\/p>\n

<\/a><\/p>\n

\nThe acquisition represents a further milestone in Biosynth\u2019s development, which broadens its capabilities and offering to the IVD industry. Aalto\u2019s product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.\n<\/p>\n

\nDr. Urs Spitz, CEO and President of Biosynth, said, \u201cThis acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.\u201d\n<\/p>\n

\nPhilip Noone, CEO of Aalto, added, \u201cWe are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto\u2019s industry leading products and key focus on emerging disease are an excellent fit with Biosynth\u2019s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.\u201d\n<\/p>\n

\nhttps:\/\/www.carbosynth.com\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Biosynth Carbosynth
\n
Aimee Cossins
\n
+44 7984 525560
\n
marketing@biosynth-carbosynth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Addition of Aalto Bio Reagents expands Biosynth Carbosynth\u2019s offer to its clinical diagnostics customers. STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (\u201cBiosynth\u201d), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (\u201cAalto\u201d), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44367","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Addition of Aalto Bio Reagents expands Biosynth Carbosynth\u2019s offer to its clinical diagnostics customers. STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (\u201cBiosynth\u201d), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (\u201cAalto\u201d), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-26T08:01:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents\",\"datePublished\":\"2022-05-26T08:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/\"},\"wordCount\":317,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220526005328\\\/en\\\/1468215\\\/21\\\/biosynth-carbosynth-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/\",\"name\":\"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220526005328\\\/en\\\/1468215\\\/21\\\/biosynth-carbosynth-logo.jpg\",\"datePublished\":\"2022-05-26T08:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220526005328\\\/en\\\/1468215\\\/21\\\/biosynth-carbosynth-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220526005328\\\/en\\\/1468215\\\/21\\\/biosynth-carbosynth-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/","og_locale":"en_US","og_type":"article","og_title":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend","og_description":"Addition of Aalto Bio Reagents expands Biosynth Carbosynth\u2019s offer to its clinical diagnostics customers. STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (\u201cBiosynth\u201d), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (\u201cAalto\u201d), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-26T08:01:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents","datePublished":"2022-05-26T08:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/"},"wordCount":317,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/","url":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/","name":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg","datePublished":"2022-05-26T08:01:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220526005328\/en\/1468215\/21\/biosynth-carbosynth-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biosynth-carbosynth-further-expands-life-sciences-platform-with-acquisition-of-aalto-bio-reagents\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44367"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44367\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}